Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$2,055 Mln
P/E Ratio
--
P/B Ratio
9.15
Industry P/E
--
Debt to Equity
0.32
ROE
-0.55 %
ROCE
-43.96 %
Div. Yield
0 %
Book Value
5.91
EPS
-3.04
CFO
$-188.77 Mln
EBITDA
$-244.17 Mln
Net Profit
$-244.61 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Tarsus Pharmaceuticals Inc (TARS)
| -11.05 | 2.41 | 4.97 | 41.12 | 38.90 | -- | -- |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
|
|---|---|---|---|---|
|
Tarsus Pharmaceuticals Inc (TARS)
| 171.20 | 38.13 | -34.84 | -45.56 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.19 | 10,117.70 | 20.54 | 23.13 | |
| 296.28 | 8,962.72 | 23.48 | 58.42 | |
| 24.72 | 9,739.03 | -- | -28.77 | |
| 101.38 | 9,903.71 | 30.43 | 14.16 |
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel... therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community malaria reduction. In addition, the company develops lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. Address: 15440 Laguna Canyon Road, Irvine, CA, United States, 92618 Read more
Co-Founder, President, CEO & Chairman
Dr. Bobak R. Azamian M.D.
Co-Founder, President, CEO & Chairman
Dr. Bobak R. Azamian M.D.
Headquarters
Irvine, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Tarsus Pharmaceuticals Inc (TARS) stood at $ 377 Mln as on 31-Dec-24
The share price of Tarsus Pharmaceuticals Inc (TARS) is $49.25 (NASDAQ) as of 17-Apr-2025 16:00 EDT. Tarsus Pharmaceuticals Inc (TARS) has given a return of 38.9% in the last 3 years.
Tarsus Pharmaceuticals Inc (TARS) has a market capitalisation of $ 2,055 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Tarsus Pharmaceuticals Inc (TARS) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Tarsus Pharmaceuticals Inc (TARS) and enter the required number of quantities and click on buy to purchase the shares of Tarsus Pharmaceuticals Inc (TARS).
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community malaria reduction. In addition, the company develops lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. Address: 15440 Laguna Canyon Road, Irvine, CA, United States, 92618
The CEO & director of Dr. Bobak R. Azamian M.D.. is Tarsus Pharmaceuticals Inc (TARS), and CFO & Sr. VP is Dr. Bobak R. Azamian M.D..
There is no promoter pledging in Tarsus Pharmaceuticals Inc (TARS).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Tarsus Pharmaceuticals Inc (TARS) | Ratios |
|---|---|
|
Return on equity(%)
|
-54.83
|
|
Operating margin(%)
|
-59.09
|
|
Net Margin(%)
|
-63.16
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Tarsus Pharmaceuticals Inc (TARS) was $0 Mln.
$-0.14
(
